TNF-α and insulin resistance: Summary and future prospects

Molecular and Cellular Biochemistry

Volumn 182, Issue 1-2, 1998, Pages 169-175

  Peraldi, Pascal ^a   Spiegelman, Bruce ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adipocyte; Insulin resistance; Insulin signaling; IRS 1; Obesity; TNF

Indexed keywords

CYTOKINE; GLUCOSE; INSULIN RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTERIOSCLEROSIS; ARTICLE; GLUCOSE HOMEOSTASIS; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; NONHUMAN; OBESITY; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; INSULIN RESISTANCE; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA;

EID: 0031892271     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006865715292     Document Type: Article

References (58)

1. Sigal RJ, Warram JH: The interaction between obesity and diabetes. Curr Opin Endocrinol Diab 3: 3-9, 1996
2. Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Dernick R, Palladino MA, Kohr WJ, Aggarwal BB, Goeddel DV: Human tumor necrosis factor: Precursor structure, expression and homology to lymphotoxin. Nature 312: 724-727, 1984
3. Gray PW, Aggarwal BB, Benton CV, Bringman TS, Henzel WJ, Jarret JA, Leung DW, Moffat BNP, Svedersky LP, Palladino MA, Nedwin GE: Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumor necrosis activity. Nature 312: 721-724, 1984
4. Fiers W: Tumor necrosis factor. FEBS Lett 285: 199-212, 1991
5. Vassalli P: The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10: 411-452, 1992
6. Tracey KJ, Cerami A: Tumor necrosis factor, and other cytokines and disease. Annu Rev Cell Biol 9: 317-343, 1993
7. Vandenabeele P, Declercq W, Beyaert R, Fiers W: Two tumor necrosis factor receptors: Structure and function. Trends Cell Biol 5: 392-399, 1995
8. Kriegler M, Perez C, DeFay K, Albert I, Lu S: A novel form of TNF/ cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF. Cell 53: 45-53, 1988
9. Mohler K, Sleath P, Fitzner J, Cerretti D, Alderson M, Kerwar S, Torrance D, Otten-Evans C, Greenstreet T, Weerawarna K, Al E: Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 370: 218-220, 1994
10. Gearing A, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson A, Drummond A, Galloway W, Gilbert R, Gordon J, Al E: Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 370: 555-558, 1994
11. Bazzoni F, Beutler B: How do tumor necrosis factor receptors work? J Inflam 45: 221-238, 1995
12. Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino JMA, Goeddel DV: The two different receptors for tumor necrosis factor mediates distinct cellular responses. Proc Natl Acad Sci USA 88: 9292-9296, 1991
13. Tartaglia L, Pennica P, Goeddel D: Ligand passing: The 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem 268: 18542-18548, 1993
14. Rothe M, Wong SC, Henzel WJ, Goeddel DV: A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 78: 681-692, 1994
15. Rothe M, Pan M, Henzel W, Ayres T, Goeddel D: The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 83: 1243-1252, 1995
16. Rothe M, Xiong J, Shu H-B, Williamson K, Goddard A, Goeddel DV: I-TRAF is a novel RAF-interacting protein that regulates TRAF-mediated signal transduction. Proc Natl Acad Sci USA 93: 8241-8246, 1996
17. Adam-Klages S, Adam D, Wiegman K, Struve S, Kolanus W, Schneider-Mergener J, Kronke M: FAN, a novel WD-repeat protein, couples the p55TNF-receptor to neutral sphingomyelinase. Cell 86: 937-947, 1996
18. Hsu H, Xiong J, Goeddel D: The TNF receptor 1-associated protein TRADD signals death and NF-κB activation. Cell 81: 495-504, 1995
19. Hsu H, Shu HB, Pan MG, Goeddel DV: TRADD-TRAF2 and TRADDFADD interactions define two distinct TNF receptor 1 signaling transduction pathways. Cell 84: 299-308, 1996
20. Stanger B, Leder P, Lee T, Kim E, Seed B: RIP: A novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 81: 513-523, 1995
21. Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV: TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4: 387-396, 1996
22. Boldin MP, Goncharov TM, Goltsev YV, Wallach D: Involvement of MACH, a novel MORT1/FADD-interacting protease, in FAS/APO-1 and TNF receptor induced cell death. Cell 85: 803-815, 1996
23. Muzio M, Chinnaiyan A, Kischkel F, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz J, Zhang M, Gentz R, Mann M, Krammer P, Peter M, Dixit V: FLICK, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85: 817-827, 1996
24. Wang C-Y, Mayo MW, Baldwin AS : TNF- and cancer therapy-induced apoptosis: potential by inhibition of NF-κB. Science 274: 784-786, 1996
25. Beg AA, Baltimore D: An essential role for NF-κB in preventing TNF-α-induced cell death. Science 274: 782-784, 1996
26. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM: Supression of TNFα-induced apoptosis by NF-κb. Science 274: 787-789, 1996
27. Liu Z-g, Hsu H, Goeddel DV, Karin M: Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death. Cell 87: 565-576, 1996
28. Van Dongen CJ, Zwiers H, Gispen WH: Purification and partial characterization of the phosphatidylinositol 4-phosphate kinase from rat brain. Biochem J 223: 197-203, 1984
29. Lang CH, Dobrescu C, Bagby GJ: Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 130: 43-52, 1992
30. Grunfeld C, Feingold K: The metabolic effect of tumor necrosis factor and other cytokines. Biotherapy 3: 143-158, 1991
31. Torti FM, Dieckmann B, Beutler B, Cerami A, Ringold GM: A macrophage factor inhibits adipocyte gene expression: An in vitro model for cachexia. Science 229: 867-869, 1985
32. Grunfeld C, Feingold K: Metabolic disturbance and wasting in the acquired immunodeficiency syndrome. N Engl J Med 327: 329-337, 1992
33. Copeland GP, Leinster SJ, Davis JC, Hipkin LJ: Insulin resistance in patient with colorectal cancer. Br J Surg 74: 1031-1035, 1987
34. Marano M, Moldawer L, Fong Y, Al E: cachectin/TNF production in experimental burns and pseudonomas infection. Arch Surg 123: 1383-1388, 1988
35. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-α: Direct role in obesity-linked insulin resistance. Science 259: 87-91, 1993
36. Hofmann C, Lorenz K, Braithwaite SS, Colca JR, Palazuk BJ, Hotamisligil GS, Spiegelman BM: Altered gene expression for tumor necrosis factor-α and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 134: 264-270, 1994
37. Lowell BB, Susulic S, Hamann A, Lawitts JA, Himms H-J, Boyer BB, Kozak LP, Flyers JS: Development of obesity in transgenic mice after genetic ablation of brown adipose tissue. Nature 366: 740-742, 1993
38. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 95: 2409-2415, 1995
39. Kern P, Saghizadeh M, Ong J, Bosch R, Deem R, Simsolo R: The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 95: 2111-2119, 1995
40. Saghizadeh M, Ong JM, Garvey TW, Henry R, Kern PA: The expression of TNF-α by human muscle. J Clin Invest 97: 1111-1116, 1996
41. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM: Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. J Clin Invest 94: 1543-1549, 1994
42. Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM: Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 274: 1377-1379, 1996
43. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM: Tumor necrosis factor a inhibits signaling from the insulin receptor. Proc Natl Acad Sci 91: 4854-4858, 1994
44. Stephens J, Pekala P: Transcriptional repression of the C/EBP-alpha and GLUT4 genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. Regulations is coordinate and independent of protein synthesis. J Biol Chem 267: 13580-13584, 1992
45. Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik A: Tumor necrosis factor-α suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 268: 26055-26058, 1993
46. Peraldi P, Hotamisligil GS, Buurman WA, White MF, Spiegelman BM: Tumor necrosis factor (TNF)-α inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J Biol Chem 271: 13018-13022, 1996
47. Kroder G, Bossenmayer B, Kellerer M, Capp E, Stoyanov B, Muhlhofer A, Berti L, Horikoshi H, Ullrich A, Haring H: Tumor necrosis factor α and hyperglycemia-induced insulin resistance. J Clin Invest 97: 1471-1477, 1996
48. White MF, Kahn CR: The insulin signaling system. J Biol Chem 269: 1-4, 1994
49. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α-and obesity-induced insulin resistance. Science 271: 665-668, 1996
50. Kanety H, Feinstein R, Papa M, Hemi R, Karasik A: Tumor necrosis factor-α-induced phosphorylation of insulin receptor substrate-1 (IRS-1). J Biol Chem 270: 23780-23784, 1995
51. Kolesnick R, Golde D: The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell 77: 325-328, 1994
52. Lozano J, Berra E, Municio M, Diaz-Meco M, Dominguez I, Sanz L, Moscat J: Protein kinase C isoform is critical for kappa B-dependent promoter activation by sphingomyelinase. J Biol Chem 269: 19200-19202, 1994
53. Muller G, Ayoub M, Storz P, Rennecke J, Fabbro D, Pfizenmaier K: PKC ζ is a molecular switch in signal transduction of TNF-α bifunctionally regulated by ceramide and arachidonic acid. EMBO J 14: 1156-1165, 1995
54. Yao B, Zhang Y, Delikat S, Mathias S, Basu S, Kolesnick R: Phosphorylation of Raf by ceramide-activated protein kinase. Nature 378: 307-310, 1995
55. Dobrowsky R, Hannun Y: Ceramide stimulates a cytosolic protein phosphatase. J Biol Chem 267: 5048-5051, 1992
56. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R: Effects of an engineered human anti-TNF-α antibody (CPD571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45: 881-885, 1996
57. Boden G, Chen X, Ruiz J, White JV, Rosseti L: Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 93: 2438-2446, 1994
58. Muller HK, Kellerer B, Ermel A, Muhlhofer B, Obermaier-Kusser B, Vogt B, Haring HC: Prevention by protein kinase C inhibitors of glucose-induced insulin receptor tyrosine kinase resistance in rat fat cells. Diabetes 40: 1440-1448, 1991